Industrial Hemp Innovator Medical Marijuana, Inc. Well-Positioned to Expand Operations Into Full- Spectrum Cannabis Investments With Federal Legalization
San Diego, CA – April 15, 2016 – Medical Marijuana, Inc. (OTC: MJNA) recognizes and applauds the significant accomplishment of Pennsylvania as the 24th U.S. state or district that is set to allow access to medical cannabis (marijuana). News reports indicate that the Governor will sign the bill on Sunday. Including U.S. territories Puerto Rico and Guam as well as the District of Columbia, Pennsylvania’s milestone achievement translates to more than 50% of all U.S. locations and 51.26% of U.S. population with full-spectrum medical cannabis laws enacted.
|U.S. States & District of Columbia Population||321,418,820|
|Total U.S. states, district, territories population||325,062,863|
|Total U.S. population with medical marijuana laws||166,632,385|
|Percent U.S. population with medical marijuana access||51.26%|
(Statistics from: U.S. Census 2015 Population, ProCon.org)
In addition, there are 16 U.S. states with limited medical cannabis access laws enacted. This brings the total of all U.S. states, district or territories with some form of cannabis law to 42.
“It is clear that cannabis has reached the tipping point in the minds of the U.S. population,” states Dr. Stuart Titus, Chief Executive Officer of MJNA. “With the re-introduction of cannabis as a wellness option, residents of Pennsylvania will soon have the ability to choose from natural products, pharmaceuticals or a combination of both.”
The Center for Disease Control (CDC) website states, “At least half of all opioid overdose deaths involve a prescription opioid.” Data from the National Survey on Drug Use and Health (NSDUH) also states, “Prescription drug abuse in the U.S. is the fastest-growing drug problem.”
In contrast, a NORML article explains that in a study published online in The American Journal on Addictions, investigators at the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia assessed the use of cannabis in 91 opiate-dependent subjects undergoing methadone maintenance treatment. Researchers found that subjects seeking methadone treatment who acknowledged a history of cannabis use reported “significantly less daily expenditure on acquisition of opiates.”
Titus continues, “The power to choose is critical. With prescription opioid abuse and deaths on the rise and now listed as the country’s No. 1 epidemic, research proves that, in states with legalized medical cannabis access, there are 25 percent fewer deaths from prescription drug overdoses.”
“Also noteworthy in many medical-marijuana-legal states is that we are now seeing an expansion of the number of potential allowable indications for doctors to recommend medicinal cannabis to patients. In Pennsylvania, as many as 18 medical conditions are slated to be allowed under this progressive program, potentially allowing access for a significant number of Pennsylvania state residents,” concludes Titus.
Pennsylvania’s SB3 explains qualified medical conditions as: “Patients could qualify for medical cannabis if they have a terminal illness or if they suffer from cancer, HIV/AIDS, amyotrophic lateral sclerosis, Parkinson’s disease, multiple sclerosis, epilepsy, inflammatory bowel disease, neuropathies, Huntington’s disease, Crohn’s disease, post-traumatic stress disorder, intractable seizures, glaucoma, autism, sickle cell anemia, damage to the nervous tissue of the spinal cord with objective neurological indication of intractable spasticity, and severe chronic or intractable pain of neuropathic origin, or if conventional therapeutic intervention and opiate therapy is contraindicated or ineffective.”
Medical Marijuana, Inc.’s current investments are in both the marijuana services and industrial hemp cannabidiol (CBD) industries; industrial hemp-based products are available to ship to all 50 states, districts, territories and more than 40 countries. As evidenced by the Company’s international distribution of hemp CBD retail products to Brazil and Mexico by way of government-issued import permits, the global demand for legal cannabis products is on the rise. MJNA is also focused on investments that are developing cannabis-based pharmaceutical drug development for global distribution.
When Federal legalization of marijuana occurs in the U.S., Medical Marijuana, Inc. will easily transition into operational expansion of marijuana-derived product production, marketing and distribution. For more information on Medical Marijuana, Inc. visit the company’s website.
About Medical Marijuana Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
The Company is committed to consistently providing the highest-quality CBD hemp oil products on the market. To see Medical Marijuana, Inc.’s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp- based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
For further information, please contact: Public Relations contact:
[email protected] www.cmwmedia.com
Corporate contact: Medical Marijuana, Inc.
Toll Free: 888-OTC-MJNA (888-682-6562)
Investor Relations: Nicholas R. Massalas
Director of Business Development Medical Marijuana Inc.
OTC Symbol: MJNA
Toll Free: (877) 964.6463 Direct: (858) 264-6505
Email: [email protected]